Masturah Bte Mohd Abdul Rashid
Research Subjects
Masturah Bte Mohd Abdul Rashid has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Anand Devaprasath Jeyasekharan
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3 shared publications - Chandramouli Nagarajan
Department of Haematology, Singapore General Hospital, Singapore, Singapore
2 shared publications - Choon Kiat Ong
Duke-NUS Medical School, Singapore, Singapore
2 shared publications Daryl Tan
Mount Elizabeth Novena Hospital, Singapore, Singapore
2 shared publicationsEdward Kai-Hua Chow
2 shared publications- Edward Kai-Hua Chow
Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore
2 shared publications
Latest Publications
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500998
Reply to: Improving the Clinical Interpretability of Functional Drug Screens: A Suggestion for Standardized Clinical Decision Thresholds in Quadratic Phenotypic Optimization Platform
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500998
Reply to: Improving the Clinical Interpretability of Functional Drug Screens: A Suggestion for Standardized Clinical Decision Thresholds in Quadratic Phenotypic Optimization Platform
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400780
Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma
PURPOSE: Despite initially responding to first-line treatment, many patients with non-Hodgkin's lymphoma (NHL) eventually relapse or are refractory. These patients are empirically subjected to salvage therapies that may not be efficacious. We had previously presented feasibility evidence of an ex vivo functional precision medicine (FPM) platform, quadratic phenotypic optimization platform (QPOP), being potentially useful in identifying alternative therapeutic options for patients with relapsed/refractory (R/R)-NHL. We now present an analysis of the completed prospective study, with clinical concordance and benefit of QPOP in predicting treatment responses of patients with R/R-NHL. MATERIALS AND METHODS: One hundred seventeen patients with R/R B-cell NHL (B-NHL) or natural killer or T-cell NHL (NK/T-NHL) were recruited for QPOP testing. Isolated tumor cells were incubated for 48 hours with drug combinations determined by an orthogonal array composite design. QPOP reports with patient-specific optimal drug therapies were generated. Patients were given off-label treatments according to the clinician's decision. Patient characteristics and responses to treatments after QPOP testing were recorded. RESULTS: Within 126 QPOP cases, 105 (52 B-NHL and 53 NK/T-NHL) were evaluable. QPOP-suggested drug responses were concordant with actual patient outcome, with an overall test accuracy of 74.5%. An overall response rate of 59% was achieved in those prescribed off-label QPOP-guided combinations. In all, 59.3% of QPOP-guided patients had improved response durations compared with their previous treatment. Compared with those who received salvage therapy, QPOP-guided patients also had longer progression-free survival 2 years after treatment. CONCLUSION: There is increasing evidence that genetic factors are not sole determinants of patient drug response and FPM approaches may improve cancer treatment guidance. This study further confirms that advancements in ex vivo combinatorial drug screening platforms like QPOP could complement existing genomic methods in identifying effective treatment options for patients with cancer, especially in R/R cases.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400780
Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma
PURPOSE: Despite initially responding to first-line treatment, many patients with non-Hodgkin's lymphoma (NHL) eventually relapse or are refractory. These patients are empirically subjected to salvage therapies that may not be efficacious. We had previously presented feasibility evidence of an ex vivo functional precision medicine (FPM) platform, quadratic phenotypic optimization platform (QPOP), being potentially useful in identifying alternative therapeutic options for patients with relapsed/refractory (R/R)-NHL. We now present an analysis of the completed prospective study, with clinical concordance and benefit of QPOP in predicting treatment responses of patients with R/R-NHL. MATERIALS AND METHODS: One hundred seventeen patients with R/R B-cell NHL (B-NHL) or natural killer or T-cell NHL (NK/T-NHL) were recruited for QPOP testing. Isolated tumor cells were incubated for 48 hours with drug combinations determined by an orthogonal array composite design. QPOP reports with patient-specific optimal drug therapies were generated. Patients were given off-label treatments according to the clinician's decision. Patient characteristics and responses to treatments after QPOP testing were recorded. RESULTS: Within 126 QPOP cases, 105 (52 B-NHL and 53 NK/T-NHL) were evaluable. QPOP-suggested drug responses were concordant with actual patient outcome, with an overall test accuracy of 74.5%. An overall response rate of 59% was achieved in those prescribed off-label QPOP-guided combinations. In all, 59.3% of QPOP-guided patients had improved response durations compared with their previous treatment. Compared with those who received salvage therapy, QPOP-guided patients also had longer progression-free survival 2 years after treatment. CONCLUSION: There is increasing evidence that genetic factors are not sole determinants of patient drug response and FPM approaches may improve cancer treatment guidance. This study further confirms that advancements in ex vivo combinatorial drug screening platforms like QPOP could complement existing genomic methods in identifying effective treatment options for patients with cancer, especially in R/R cases.
- 19 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (667) , eabn7824
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin’s lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options ( n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo–guided combination therapy in RR-NHL.
- 19 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (667) , eabn7824
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin’s lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options ( n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo–guided combination therapy in RR-NHL.
- Open Access
- 1 January 2021
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 36 (3) , 270-275
Ceruminous Adenoma: A Rare Mass that Impair Hearing
Ceruminous adenoma is described as a glandular neoplasm of ceruminous glands. It is seen for less than one percent of all external ear tumours. Ceruminous adenoma cases were reported to have recurrence and residual tumour, however there was no malignant transformation known in ceruminous adenoma up to this date. Here, we report a young adult woman with two years history of progressive reduced hearing and tinnitus of the right ear. She was proven to have right moderate conductive hearing loss with pure tone audiometry. There was a cystic mass with serous content arising from the posterior wall of the right ear canal. We proceeded with wide local excision of the mass via trans-canal approach. Ceruminous adenoma was confirmed with histopathology and immunohistochemistry of CK7 staining. The hearing impairment was resolved completely post excision and there was no recurrence of the tumour on one year follow-up. We concluded wide local excision with appropriate margin of the mass is adequate to prevent recurrence in ceruminous adenoma cases.
- 1 January 2021
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 36 (3) , 270-275
Open AccessCeruminous Adenoma: A Rare Mass that Impair Hearing
Ceruminous adenoma is described as a glandular neoplasm of ceruminous glands. It is seen for less than one percent of all external ear tumours. Ceruminous adenoma cases were reported to have recurrence and residual tumour, however there was no malignant transformation known in ceruminous adenoma up to this date. Here, we report a young adult woman with two years history of progressive reduced hearing and tinnitus of the right ear. She was proven to have right moderate conductive hearing loss with pure tone audiometry. There was a cystic mass with serous content arising from the posterior wall of the right ear canal. We proceeded with wide local excision of the mass via trans-canal approach. Ceruminous adenoma was confirmed with histopathology and immunohistochemistry of CK7 staining. The hearing impairment was resolved completely post excision and there was no recurrence of the tumour on one year follow-up. We concluded wide local excision with appropriate margin of the mass is adequate to prevent recurrence in ceruminous adenoma cases.
- 8 August 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (453)
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
A drug discovery and optimization platform uncovered effective therapeutic combinations for bortezomib-resistant multiple myeloma.
- 8 August 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (453)
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
A drug discovery and optimization platform uncovered effective therapeutic combinations for bortezomib-resistant multiple myeloma.